Overview

A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This trial will evaluate the effect of ASP7147 on daily abdominal pain due to IBS-D during 4 weeks of treatment. It will also evaluate safety and tolerability in patients with IBS-D over the 4-week treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
Seldar Pharma, Inc.